Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of May 2022, with a specific transaction date of May 9, 2022. The report serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It is strictly a disclosure of an insider transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of notional ADSs |
| Instrument | American Depositary Shares (ADSs) |
| Price per ADS | $43.1600 |
| Volume | 1,193.423 ADSs |
| Exchange | New York Stock Exchange (XNYS) |
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details a single acquisition event within an executive savings plan rather than a change in corporate strategy or financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transaction was executed within Dr. H. Barron's GSK Executive Supplemental Savings Plan account.
Key Facts for Investor Verification
- Insider Identity: The transaction involves Dr. H. Barron, Chief Scientific Officer and President, R&D.
- Transaction Nature: This was an acquisition of notional ADSs, not a direct open-market purchase of physical shares.
- Timing: The transaction occurred on May 9, 2022, and was reported on May 12, 2022.
- Financial Impact: The filing does not disclose the total monetary value of the transaction, only the unit price and volume.